ea0026oc2.5 | Neuroendocrinology | ECE2011
Trifiro G
, Mokhles M
, Dieleman J
, van Soest E
, Mazzaglia G
, Herings R
, de Luise C
, Ross D
, Brusselle G
, Colao A
, Haverkamp W
, Schade R
, van Camp G
, Zanettini R
, Sturkenboom M
Background: There is growing evidence that ergot dopamine agonists (DA) may induce cardiac valve regurgitation (CVR) in persons with Parkinsons disease (PD). It is unclear whether the CVR risk is increased with ergot-DA use in persons with hyperprolactinemia, in whom the dose is much lower.Objective: To assess the association between ergot and non-ergot DAs and CVR in patients with hyperprolactinemia and PD.Methods: Nested ca...